Curriculum Vitae
Abhinav Humar, M.D.

EDUCATION:

1984-88 Univ. of Ottawa Medicine MD- Magna cum laude (silver medalist) 1982-84 Univ. of Ottawa B.Sc. (Biology) Year 1 and 2 1978-81 Brookfield High School Higher Secondary Diploma Silver Medal

Top of page

POSTDOCTORAL TRAINING:

1996-98 Univ. of Minnesota Transplant Surgery Research and Clinical Fellowship 1996 Univ. of Western Ontario Transplant Surgery Clinical Fellowship- 3 months 1995-96 Univ. of Ottawa Cardiothoracic Surgery Clinical Fellowship-6 months 1990-95 Univ. of Ottawa General Surgery FRCS(C) 1989-90 Univ. of Ottawa Pediatric Medicine Clinical Fellow- 1 year 1988-89 Univ. of Ottawa Rotating Internship Completed

Top of page

LICENSURE AND CERTIFICATION:

Minnesota State Medical License

Royal College of Physicians and Surgeons  of Canada (Effective: 02/13/1997)

Top of page

ACADEMIC APPOINTMENTS:

Lecturer, University of Ottawa: 1993-96
Instructor, University of Minnesota: 1996-98
Assistant Professor, University of Minnesota: 1998-2002
Associate Professor, University of Minnesota: 2002-2006
Professor, University of Minnesota, 2006-present

Top of page

ACADEMIC ADMINISTRATIVE APPOINTMENTS:

Medical Director for the Living Donor Transplant Program
University of Minnesota: 2000-present

Service Director for house staff teaching,
Division of Transplantation, University of Minnesota: 1999-present

Top of page

CLINICAL/ HOSPITAL APPOINTMENTS:

Staff Physician, Fairview University Medical Center: 1997-present
Physician, VA Medical Center, Minneapolis: 2005-present

Top of page

CLINICAL INTERESTS:

- Adult abdominal transplants (kidney, liver, pancreas, and bowel)
- Pediatric kidney, liver, and bowel transplants
- Living-related liver transplants
- Hepatobiliary surgery
- Vascular surgery

Top of page

RESEARCH INTERESTS:

- Partial liver transplants and studies of hepatic regeneration
- Clinical outcome studies in kidney, liver and pancreas transplants
- CMV disease in transplant recipients-- prophylaxis, treatment, and clinical predictors
- Outcomes in pediatric kidney and liver transplant recipients

Top of page

PEER-REVIEWED GRANTS:

1. Clinical, Immunologic, and pharmacologic consequences of solid organ transplantation in people with HIV infection. A multi-center trial to determine safety and efficacy of kidney and liver transplantation in HIV positive patients.
NIH grant # 401A140166, 2001. (Arthur J. Matas, MD – Grant Applicant PI)
Funding institution: NIH
Principal investigator: Abhinav Humar, MD

2. Solid Organ Transplantation in HIV: Multi-Site Study, HIVTR. (Human Subjects Code 0308M51386)
Principal Investigator: Abhinav Humar, MD

3. A Multi-Center, Randomized, Open-Label Parallel Group Study to Compare Neoral with C-2h Monitoring to Tacrolimus with Trough Monitoring in De Novo Liver Transplant Recipients. (Human Subjects Code: 0106M04162)
Principal Investigator: John Lake, MD
Role: Co-investigator

4. Liver Transplant Outcomes Database (Human Subjects Code 0004M47901) Principal Investigator: Abhinav Humar, MD
Role: Principal Investigator

5. Comprehensive Follow-up of Living Donors.
Funding Institution: NIH
Principal Investigator: Arthur Matas, MD
Role: Co-investigator

6. SPLIT, Studies of Pediatric Liver Transplantation, a multicenter, prospective study to collect scientific data on pediatric liver transplantation.
Funding Institution: NIH
Principal Investigator: Abhinav Humar, MD

7. Long-term Functional Outcomes in Pediatric Liver Transplant Recipients (IRB Code Number: 0505M69929)
Funding Institution: NIH
Principal Investigator: Abhinav Humar

Top of page

INDUSTRY GRANTS:

8. Randomized, Prospective Trial of IV Ganciclovir Plus Either Oral Ganciclovir or Oral Acyclovir in the Prevention and Treatment of CMV Disease in Recipients of Solid Organ Allografts (Human Subjects Code 9607M11517), 1998.
Funding institution: Roche Pharmaceuticals
Principal investigator: David L. Dunn, MD, Ph.D.
Role: Co-investigator

9. An Analysis of Steroid Withdrawal after Pancreas Transplantation, 1998. Funding institution: Fujisawa
Principal investigator: Abhinav Humar, MD

10. A Randomized, Comparative Trial of Steroid Withdrawal vs. Steroid Maintenance after Pancreas Transplantation (Human Subjects Code 9812M00101), 1999.
Funding institution: Fujisawa
Principal investigator: Rainer Gruessner, MD
Role: Co-investigator

11. An Open-Label, Comparative Trial of Two Daclizumab Dosing Strategies versus No Induction Treatment in combination with Tacrolimus, Mycophenolate Mofetil, and Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients (Protocol Number ZEN049), 1999.
Funding institution: Roche Pharmaceuticals
Principal investigator: Abhinav Humar, MD

12. An Open-Label Active Controlled Study to Evaluate the Use of CellCept (mycophenolate mofetil, MMF) in Post-Liver Transplant Patients with Renal Impairment Who are Currently on Neoral (cyclosporine A) (Protocol Number R15714), 2000.
Funding institution: Roche Pharmaceuticals
Principal investigator: John Lake, MD
Role: Co-investigator

13. A Randomized, Open-Label Preference Study of Gengraf Compared to Neoral in Stable solid-Organ Transplant Subjects, 2000.
Funding institution: Roche Pharmaceuticals
Principal investigator: John Lake, MD
Role: Co-investigator

14. Single center analysis of recipients undergoing liver transplant recipients with renal dysfunction using Simulect, MMF, and prednisone with delayed introduction of a calcineurin inhibitor. 2000
Funding institution: Novartis Pharmaceuticals
Principal investigator: Abhinav Humar, MD

15. A Phase-II, Open-Label, Concentration Controlled, Randomized Study of Conventional-Dose Tacrolimus Plus Corticosteroids Compared with Reduced-Dose Tacrolimus Plus Sirolimus and Corticosteroids in Recipients of Orthotopic Liver Allografts. (Human Subjects Code Number: 0005M50521), 2000.
Funding institution: Wyeth Pharmaceuticals
Principal investigator: John Lake, MD
Role: Co-investigator

16. A Multicenter, Randomized, Open-Label, Parallel Group Study to Compare the Usefulness of Peak vs Trough Cyclosporine Monitoring in de novo Liver Transplant Recipients Treated with Neoral (Human Subjects Code 9809M00003), 2001.
Funding institution: Novartis Pharmaceuticals
Principal investigator: John Lake, MD
Role: Co-investigator

17. A One-Year, Multicenter, Prospective, Open-Label Study of the Safety, Tolerability and Preliminary Efficacy of Oral FTY720 and RAD001 in De Novo Adult Renal Transplant Recipients at Increased Risk of Delayed Graft Function, 2001.
Funding institution: Novartis Pharmaceuticals
Principal investigator: Abhinav Humar, MD

18. Post-Transplant Lymphoproliferative Disease: A Randomized Trial of Ganciclovir and Immune Globulin Prophylaxis among Solid Organ Transplant Recipients. Supported by a grant from the Hospital of Sick Children, Toronto, Canada, 2001.
Funding institution: Medimmune
Principal investigator: Abhinav Humar, MD

19. SPLIT, Studies of Pediatric Liver Transplantation, a multicenter, prospective study to collect scientific data on pediatric liver transplantation. Supported by a grant from Fujisawa, 2001.
Funding institution: Fujisawa
Principal investigator: Abhinav Humar, MD

20. Prospective, Open-label, randomized comparative trial of Mycophenolate Mofetil Versus Sirolimus, with Steroid withdrawal, using a Tacrolimus based immunosuppressive protocol, 2001.
Funding institution: Roche Pharmaceuticals
Principal investigator: Raja Kandaswamy, MD
Role: Co-investigator

21. A Prospective, Open-label, Randomized trial of steroid avoidance using a sirolimus/tacrolimus based immunosuppressive protocol in simultaneous pancreas-kidney transplantation. 2001.
Funding institution: Wyeth-Ayerst Pharmaceuticals
Principal investigator: Raja Kandaswamy, MD
Role: Co-investigator

22. Post-Transplant Lymphoproliferative Disease: A Randomized Trial of Ganciclovir and Immune Globulin Prophylaxis Among Solid Organ Transplant Recipients. (Human Subjects Code: 0105M99261)
Funding Institution: Medimmune
Principal Investigator: Abhinav Humar, MD

23. A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus disease in High-Risk Kidney Allograft Recipients.
Funding Institution: Roche Pharmaceuticals
Principal Investigator: Abhinav Humar, MD

24. A Prospective, Randomized Study of Cyclosporine/MMF vs. Tacrolimus/Sirolimus in a Steroid Avoidance Protocol. (Human Subjects Code 0011M74301)
Funding Institution: Fujisawa/Sangstat/NIH
Principal Investigator: Arthur Matas, MD
Role: Co-investigator

25. Calcineurin Withdrawal in Liver Transplant Recipients. Supported by a graft from Roche Lab.
Funding Institution: Roche Lab
Principal Investigator: Abhinav Humar, MD

26. A Randomized, Controlled, Multicenter Study of Thymoglobulin Induction Therapy with a Calcineurin-Inhibitor Sparing Regimen in Liver Transplant Patients. (Genzyme Protocol#: THYMO102700103) (Human Subjects Code: 0402M56941) (PRDU Number: 02.2004.01)
Funding Institution: Genzyme
Principal Investigator: John Lake, MD
Role: Co-investigator

27. A Prospective, Randomized, Multicenter, Open-Label, Comparative Safety and Efficacy Study of Prophylactically Administered Pegylated Interferon alfa-2a (Pegasys) Plus Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C. (Sponsor protocol: ML18124)
Funding Institution: Roche
Principal Investigator: John Lake, MD
Role: Co-investigator

28. Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected with Hepatitis B Virus with Evidence of Lamivudine Resistance and Hepatic Decompensation.
Clinical Protocol AI463048. 2003.
Funding Institution: Bristol-Meyers Squibb
Principal Investigator: John Lake, MD
Role:Co-investigator

29. A Phase II, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-Term Safety and Tolerability of Tacrolimus in Stable Liver Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen. (Human Subjects Code 0212M38141)
Funding Institution: Astellas Pharma US Inc.
Principal Investigator: Abhinav Humar, MC
Role: Principal Investigator

30. A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor treatment in Liver Allograft Recipients Undergoing Maintenance Therapy. (Human Subjects Code: 0205M24065)
Funding Institution: Wyeth-Ayerst Research
Principal Investigator: Abhinav Humar, MD

31. A Phase II, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-Term Safety and Tolerability of Tacrolimus in Stable Kidney Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen. (Human Subjects Code 0212M33801)
Funding Institution: Fujisawa
Principal Investigator: Arthur Matas, MD
Role: Co-investigator

32. A Prospective, Randomized, Open-Label, Twenty-six Week Study of the Efficacy and Safety of Converting Kidney and Liver Transplant Recipients with Tacrolimus-associated bnormal Glucose Metabolism to Neoral with C2 Monitoring. (Sponsored Protocol #: COLO400A US06)
Funding Institution: Novartis Pharmaceuticals Corporation
Principal Investigator: John Lake, MD
Role: Co-investigator

33. A prospective, open-label, multi-center, randomized trial of the efficacy and safety of a long term calcineurin inhibitor free maintenance regimen with mycophenolate mofetil and sirolimus in recipients of an orthotopic liver transplant
Funding Institution: Roche Pharmaceuticals Corporation
Principal Investigator: Abhinav Humar

34. Belatacept Evaluation of Nehproprotection and Efficacy as First-line Immuno-suppression Trial – Regular criteria donors (BENEFIT)
Funding Institution: Bristol-Meyers Squibb
Principal Investigator: Abhinav Humar, MD

35. REP024: A Phase II, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel-Group (3 Arms) Pilot Study to Assess the Efficacy, the Safety and the Pharmacokinetics of Two Treatment Scheduled of Reparixin in the Prevention of Delayed Graft Function after Kidney Transplantation in High-Risk Patients. Human Subjects Code: 0506M70288
Funding Institution: Dompe
Principal Investigator: Abhinav Humar, MD

36. An Open-Label Study of the Safety and Efficacy of Adefovir Dipivoxil for the Treatment of Liver Disease Due to Lamivudine-Resistant Hepatitis B (HBV) in Liver Transplant Patients
Funding Institution: Gilead Sciences, Inc.
Principal Investigator: Abhinav Humar, M.D.
Role: Co-Principal Investigator

37. Zygomycetes in Organ Transplant Recipients: A Case Controlled Study to Assess Risk Factors and Outcomes
Principal Investigator: Abhinav Humar, M.D.

38. A Randomized, Double-Blind, Double-Dummy Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir versus Oral Ganciclovir for the Prevent of Cytomegalovirus in Recipients of Orthotopic Liver Transplants
Funding Institution: ViroPharma, Inc.
Percent Effort:
Principal Investigator: Abhinav Humar, M.D.
Role: Principal Investigator

39. A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant
Funding Institution: Bristol-Myers Squibb
Principal Investigator: Abhinav Humar, M.D.

40. IMPACT: A Randomized, Double-Blind, Placebo, Controlled, Multi-
Funding Institution: Hoffman La Roche Pharm
Role: Principal Investigator, 6/24/06-10/8/09

41. Phase IIIb, Randomized, Open-Label, Comparative, Multi-Center Study to Assess Safety and Efficacy of Prograf vs. MR Tacrolimus w/CellCept and Steroid Withdrawl in de novo Liver Transplant Recipients
Funding Institution: Astellas Pharma US, Inc.
Role: Principal Investigator, 3/29/06-8/31/08

42. Calcineurin-sparing in a steroid-free maintenance immunosuppression protocol
Funding Institution: Wyeth Pharmaceuticals
Principal Investigator: Arthur Matas, M.D.
Role: Co-Investigator, 6/26/07-9/30/11

43. A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease.
Funding Institution: Viropharma Inc.
Role: Principal Investigator, 8/01/07 – 11/03/09

Top of page

SCIENTIFIC ACTIVITIES:

Scientific Journals

Ad hoc reviewer for Transplantation, American Journal of Nephrology, American Journal of Transplantation, Transplantation, Transplant International: 1999-present

Editorial Board for Clinical Transplantation:  1999-present
Editorial Board for Liver Transplantation: 2002-present
Physician Advisory Panel – Medica: 2003-present

Scientific Meetings

Abstract reviewer for American Transplant Congress : 2001-2005
Abstract reviewer for American Society of Transplant Surgery Winter Symposium, 2004
Organizing Committee for American Society of Transplant Surgery Winter Symposium, 2004
Organizing Committee for Asian Pacific Association for the Study of Liver Disease Annual meeting, 2004

Scientific Organizations

Medical Advisory Committee, Minnesota Chapter of the American Liver Foundation, 2002 - present

Co-chair of the Awards Committee of the American Society of Transplant Surgeons, 2004-2007

American Society of Transplantation Infectious Disease Community of Practice Committee, member, 2005-present

Top of page

RECOGNITIONS:

Selected as a Top Doctor in Minneapolis-St. Paul Magazine, 2005 and 2006

Top of page

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES:

American Society of Transplant Surgeons: 1999-present
International Liver Transplantation Society: 2002-present
Society of University Surgeons: 2007-present

Top of page

COURSES:

Laboratory Microsurgery Course, University of Ottawa, Sept 1992
Advanced Trauma Life Support, University of Minnesota, 1997
Basic CPR Course, VA medical center, 2006

Top of page

TEACHING ACTIVITIES:

During Residency

1. Lecturer for GI Block Case Discussions, University of Ottawa; 1993-95
2. Tutor for GI Block Physical Diagnosis, University of Ottawa. 1994-95
3. Instructor for Technical Skills Laboratory Course for Junior Surgical Residents; 1994-95
4. Assistant in organizing “Mini - Statistical Course” for Surgical Residents; 1995
5. PAIRO (Professional Association of Interns and Residents of Ontario) Residents Excellence in Clinical Teaching Award. June 1995

Current

1. Service Director for Transplant surgery at University of Minnesota; 1999-present: coordinating teaching activities for all interns and residents on transplant surgery and performing their evaluations at the end of the rotation.  Responsibilities include: supervising Transplant Teaching Conference for Surgical Residents, design curriculum, overseeing delivery of lectures.

2. Member of University of Minnesota Transplant training program: advising and mentoring for transplant fellows.: 1998-present.

3. Summer mentorship program for pre-medical students.  This program provides one-on-one mentoring for undergraduate students interested in pursuing a career in medicine.

4. Medical student surgery core curriculum teaching lecture, University of Minnesota. 2004-present

5. General medical residents core curriculum lecturer for the Department of Medicine, Division of Cardiology: 2004-present

6. Nephrology fellows care curriculum lecturer for the Division of Nephrology: 2004-present

7. ICU fellows core curriculum lecturer for the Department of Surgery: 2003-present

8. Anesthesia residents core curriculum lecturer for the Department of Anesthesiology, 2004-present

9. Lecturer for the Department of Pediatrics, division of Critical Care

Top of page

EXTRAMURAL INVITED PRESENTATIONS:

1. Abdominal trauma.  Second Annual Spring Conference on Critical Care and Trauma, CACCN Ottawa Region Chapter, Ottawa. May 1995.

2. Pediatric living related liver/bowel transplants—the donor’s perspective.  Fourth Annual Pediatric Critical Care Conference.  University of Minnesota, Minneapolis, April 20, 1998.

3. Current philosophy of immunosuppression in kidney transplant recipients.  North American Transplant Coordinators Organization.  San Diego Mar 1997.

4. Implications, indications, and impact of liver transplantation.  Society of Gastroenterology Nurses and Associates, Minneapolis, 1999.

5. Evidence for long-term nephrotoxicity in kidney transplant recipients.  Posttransplant Immunosuppression: New paradigms.  Minneapolis MN, Oct 1999.

6. Living-donor lobar and cadaver split liver transplantation.  The Cutting Edge—New Frontiers in transplantation.  Minneapolis, MN.  May 2000.

7. Kidney transplantation in the 1st year of life.  3rd Annual meeting of the Transplant Society of South America.  Montevideo, Uruguay.  March 2000.

8. Pancreas transplantation in the third world. 3rd Annual meeting of the Transplant Society of South America.  Montevideo, Uruguay.  March 2000.

9. Kidney vs. pancreas transplant in the diabetic. 3rd Annual meeting of the Transplant Society of South America.  Montevideo, Uruguay.  March 2000.

10. Living donor and split liver transplants.  International Meeting On Organ Donation And Pancreas transplants.  Murcia, Spain.  May 2000

11. Surgical complications after pancreas transplants.  International Meeting On Organ Donation And Pancreas transplants.  Murcia, Spain.  May 2000

12. New horizons in gastrointestinal transplant therapy.  Society of Gastroenterology Nurses and Associates, Mankato MN.  Oct 2000.

13. Laparoscopic donor nephrectomy.  International multispecialty medical update and CME program.  Bangalore, India. Dec 2000.

14. Living donor liver transplants.  International multispecialty medical update and CME program.  Bangalore, India. Dec 2000.

15. Update on pancreas transplant. Bombay Surgical Society.  Dec 2000.

16. Use of living donors in transplantation.  Udaipur Surgical Society, Dept of Surgery, RNT Medical College, Udaipur, India.  Dec 2000.

17. Chronic rejection:  the challenge of the future.  Transplant Pharmacist Advisory Meeting.  Tuscon, Arizona, March 2001.

18. Surgical option for the uremic diabetic.  Diabetes and Transplantation:  a common horizon.  London, Ontario, April 2001.

19. PAK vs. SPK, 2nd Annual Cutting Edge Conference, Minneapolis, April, 2001.

20. Improved outcomes in pancreas after kidney transplantation.  Humar A.  2nd Annual Cutting Edge Conference, Minneapolis, Minnesota, April 18, 2001.

21. Surgical options for the uremic diabetic patient.   “Diabetes and Transplantation:  A Common Horizon.”  First Annual Symposium at The John P. Robarts Research Institute.  London, Ontario, Canada, April 2001.

22. Kidney Transplantation in the First Year of Life.  Pediatric Grand Rounds.  University of Minnesota.  May 23, 2001.

23. Long-term renal function – optimal immunosuppression regimens.  Midwest Regional Advisory Board, Lake Geneva, September 21, 2001.

24.  Techniques to expand the liver donor pool.  Medicine Grand Rounds, University of Minnesota, September 27, 2001.

25. Update on CMV in transplantation.  Transplant Grand Rounds.  Abbott Northwestern Hospital.  Oct 9, 2001.

26. Increasing the donor pool.  Transplant Immunosuppression 2001 – the compleat care of the transplant recipient.  Minneapolis, October 2001.

27. Cadaver pancreas after living donor kidney.  Transplant Immunosuppression 2001 – the compleat care of the transplant recipient.  Minneapolis, October 2001.

28. Expanding the donor pool.  3rd Annual Cutting Edge Conference,  Minneapolis, March 20, 2002.

29. Split liver transplant for 2 adult recipients.  Transplant Grand Rounds.  Mayo Clinic, Rochester, Minnesota.  April 23, 2002

30. Slow graft function after kidney transplant.  Transplant Grand Rounds.  Kansas City.  May, 2002.

31. Steroid Avoidance protocols after kidney and pancreas transplant.  Transplant Grand Rounds. Kansas City, May 2002.

32. Thymoglobulin induction in a steroid-avoiding protocol.  Thymoglobulin Clinical Advisory Meeting.  San Francisco, June 2002.

33. Recent developments in pediatric liver and intestinal transplantation.  Nursing Care of the Hospitalized Child, Minneapolis, June 22, 2002.

34. Developments in the science of pancreas and islet transplantation.  United Networks 11th Annual National Clinical Conference.  Minneapolis, Sept 2002.

35. Steroid sparing protocols.  Kansas City, October 9, 2002.

36. Immunosuppression changes.  Transplant Grand Rounds.  Kansas City, October 11, 2002

37. Living donor liver transplant.  American Liver Foundation, St. Paul, Nov. 19, 2002.

38. Kidney transplant: the surgical procedure/preservation.  Renal Fellow Seminar, University of Minnesota, December 13, 2002.

39. Expanding the donor pool.  Medical Grand Rounds, Minneapolis, February 6, 2003.

40. New Options for immunosuppression in kidney transplant patients. San Francisco, March 1, 2003.

41. Liver transplant update.  United Resource Network, Minneapolis, March 5, 2003

42. Desensitizing protocols for kidney transplant recipients.  4th Annual Cutting Edge Conference, Minneapolis, March 2003.

43. Split-liver transplants. Transplant Conference.  Wisconsin, March 24, 2003.

44. Pancreas and islet transplants. Mayo Clinic, Transplant Conference.  Scottsdale, April 3-5, 2003.

45. Immunosuppression minimization.  Pharmacy advisory board, New York City, May 16, 2003.

46. Expanding the living donor pool.  LifeSource, Minneapolis, June 10, 2003.

47. Split liver transplant for 2 adult recipients. Satellite symposium of the International Liver Transplant Society Annual Meeting, June 18, 2003.  Barcelona, Spain.

48. Steroid-Free Immunosuppression Following Kidney Transplantation.  Advances in Transplantation.  September 8-10, 2003.  Chicago.

49. Update and Outcomes in Islet Transplantation and the Artificial Pancreas.  United Resource Networks 12th Annual Conference, Sept. 14-16, 2003.  Minneapolis.

50. Immunologic Risk Factors for Kidney Graft Loss.  Transplant Immunosuppression 2003.  Minneapolis, Minnesota

51. Risk Factors and Outcomes after LD and Split Liver Transplants.  Transplant Immunosuppression 2003.  Minneapolis, Minnesota

52. Donor and Recipient Outcomes in Adult LDLT.  AASLD/ILTS Postgraduate Transplant Course.  Boston, Oct 2003.

53. Split Liver Transplant for two Adult Recipients.  ASTS Winter Symposium.  Scottsdale, Jan 2004.

54. A New Look at Antibody Therapy in Organ Transplantation: prevention of ischemia reperfusion injury and effects on renal graft function.  Moderator, Sangstat Audioconference, Dec 03-Feb 04.

55. Process of Care for Renal Transplantation: immunosuppressive treatment options in renal transplantation. Panel discussion – a review and analysis by expert key opinion leaders in renal transplantation on the latest evidence-based data on immunosuppressive treatment options in renal transplantation.  Jan 24, Scottsdale, AZ

56. Living Donor Liver Transplantation- when is this a viable option.  Liver update of the American Liver Foundation.  Minneapolis, Jan 31, 04.

57. Steroid sparing regimens in kidney transplant recipients.  Transplant grand rounds.  Rush University Medical Center.  March 4, 2004.

58. Advances in Living Donor Transplantation.  5th Annual Cutting Edge Conference, Minneapolis, April 7, 2004.

59. Steroid sparing regimens in kidney transplant recipients.  Transplant grand rounds.  Cal Pacific Medical Center. San Francisco , April 16, 2004.

60. Minimizing Immunosuppression In Renal Transplant Recipients, Nephrology Rounds, Wichita, April 27, 2004.

61. Transplant Update 2004.  General Surgery Grand Rounds.  Wichita, April 28, 2004.

62. Cadaver Split Liver Transplant for 2 Adult Recipients.  Transplant Rounds.  Tampa, April 28, 2004.

63. Steroid sparing regimens in kidney transplant recipients.  Transplant grand rounds.  Albert Einstein Medical Center, Philadelphia, May 2004.

64. Split liver transplants.  GI evening rounds.  Albert Einstein Medical Center.  Philadelphia.  May 2004.

65. Calcineurin Sparing Protocols in Kidney Transplant.  Transplant conference, Leeds meeting.  Little Rock, AR.  May 2004

66. Full Right and Left Lobe Splits.  Live Donor Liver Transplantation in the UK- A Debate.  Leeds, UK.  Nov 2004.

67. Living Kidney Donation—Methods to Expand the Donor Pool.  Nephrology Information Day.  Minneapolis, MN.  Nov 2004.

68. Living donor liver transplant: the con.  Asian Pacific Association for the Study of Liver Diseases (APASL).  New Delhi. India.  Dec 2004

69. Expanding the donor pool.  Asian Pacific Association for the Study of Liver Diseases (APASL).  New Delhi. India.  Dec 2004

70. Split Liver transplant in Adult Recipients.  Hepatology Conference, University of Texas.  Houston, Texas.  Jan 2005

71. mTOR Inhibition: the good and the bad.  American Society of Transplant Surgeons Winter Symposium.  Miami, FL.  Jan 2005

72. Recipient selection and Immunosuppression options.  Nephrology conference.  Scripps Medical Center. LaJolla, CA  Feb 2005

73. Expanding the donor pool for kidney transplant recipients.  Nephrology transplant conference.  University of Ottawa.  Feb 2005

74. Surgical innovations in transplant.  Surgery grand rounds.  Visiting Professor.  University of Ottawa.  Feb 2005

75. Recent trends in immunosuppression minimization in kidney transplant recipients.  Nephrology Journal club.  University of Western Ontario.  Hamilton, ON.  March 2005.

76. How immunosuppression has changed.  Transplant conference.  St Michaels Hospital.  Toronto, Ontario.  March 2005.

77. Surgical options for the treatment of diabetes.  Transplant Evening Conference, University of Toronto.  March 2005.

78. Split liver transplant for 2 adult recipients.  Transplant conference.  University of Toronto.  Toronto ON.  March 2005

79. Pancreas/Islet Cell Transplantation 2005.  Celebration Symposium Renal/Pancreas Transplantation 2005.  Portland, OR.  March 12, 2005.

80. Steroid sparing options for kidney transplant recipients. Transplant conference.  University of Pennsylvania.  Philadelphia.  March 16, 2005.

81. Update on Pancreas and Islet Transplantation.  National Congress of Diabetes, Antalya, Turkey.  Antayla, Turkey. May 2005

82. Post-Transplant Lymphoproliferative Disease and EBV Update.  North American Transplant Coordinator Organization 30th Annual Meeting.  Atlanta, GA.  August 2005.

83. The Surgical Treatment of Diabetes.  North American Transplant Coordinator Organization 30th Annual Meeting.  Atlanta, GA.  August 2005.

84. CMV Treatment and Prevention in Pancreas Transplant Recipients.  State of the Art Management of CMV Infection and Disease in Transplant Recipients.  Boston MA, Aug 2005

85. Minimizing surgical complications after pancreas transplant.  Indian Society of Organ Transplant.  Jaipur, India.  September 2005.

86. Expanding the donor pool for liver transplant.  Jaipur, India.  September 2005.

87. Recurrence of viral diseases after liver transplant.  Jaipur, India.  September 2005.

88. Steroid sparing regimens in transplant.  Jaipur, India.  September 2005.

89. Hepatocellular carcinoma in cirrhosis: transplant vs. resection.  The Liver: An Update, Jaslok Hospital and Research Center, Mumbai, India, December 2005.

90. Living related liver transplantation.  The Liver: An Update, Jaslok Hospital and Research Center, Mumbai, India, December 2005.

91. Surgery for metastatic liver disease: is it worth it?  The Liver: An Update, Jaslok Hospital and Research Center, Mumbai, India, December 2005.

92. Standard hepatectomy techniques.  The Liver: An Update, Jaslok Hospital and Research Center, Mumbai, India, December 2005.

93. Split liver transplant for 2 adult recipients.  Transplant grand rounds.  Lexington.  May 2006.

94. Immunosuppression minimization trends in kidney transplant recipients.  UROCON meeting of Pakistan Urologic Society.  May 2006

95. Split liver transplantation.  Advances in Hepatic, Biliary, and Pancreatic Surgery” University of Minnesota Annual Surgery Course.  June 2006.

96. EBV and PTLD: not just a disease in pediatric patients.  NATCO annual meeting.  Aug 2006. Chicago.

97. Changing face of infections in transplant recipients.  International meeting for Surgical Infections.  Stockholm.  Sept 2006.

98. Splitting livers to maximize the donor pool.  Transplant grand rounds.  Houston.  Nov 2006.

99. State-of-the-Art Management of Cytomegalovirus Infection and Disease in Transplant Recipients.  Grand Rounds, Abbott Northwestern Hospital, Minneapolis, MN.  January 2007.

100. EBV and PTLD in the Transplant Recipient.  8th Annual Cutting Edge Conference: New Frontiers in Transplantation, Minneapolis, MN, March 14, 2007.

101. The Current Status of Liver Resection.  Fairview-Southdale Hospital Grand Rounds, Edina, MN.  July 26, 2007.

102. What’s New in Liver Transplant?”  Liver Transplant Update.  Jaslok Hospital, Mumbai, India.  August 2007.

103. Immunosuppression for Liver Transplantation – current trends.  Liver Transplant Update.  Jaslok Hospital, Mumbai, India.  August 2007.

104. What’s New in Liver Transplant Immunosuppression?  Transplant Immunosuppression 2007:  the Ongoing Search for Improvement.  Minneapolis, MN, October 17-20, 2007.

105. Should Steroids be Restarted after Treatment for AR?  Transplant Immunosuppression 2007:  the Ongoing Search for Improvement.  Minneapolis, MN, October 17-20, 2007.

106. Pancreas Acceptance.  ASTS Annual Surgical Fellows Symposium, Maui, Hawaii, November 7-11, 2007.

Top of page

ADMINISTRATIVE SERVICE:

Uni of MN Medical School Admissions Committee member: 2003, 2004, 2005
Transplant Surgery Strategy Council member: 2003-present
OTTR Database Committee member: 2003-present
Fairview Transfusion Committee member: 2000-present
Education and Training Departmental Task Force member: 2005
Public Relations and Communication Departmental Task Force, chair: 2005

Top of page

BIBLIOGRAPHY:

Peer-Reviewed Articles

1. Humar A, Pitters C.  Emergency Department Management of Blunt Cervical Tracheal Trauma in Children.   Pediatric Emergency Care, 1991, 7(5): 291-293.

2. Humar A, Chou S, and Carpenter B.  Fibromatosis in Infancy and Childhood:  The Spectrum.   Journal of Pediatric Surgery, 1993, 28(11): 1446-1450.

3. Humar A, Barron P, Sekar A, and Lum A.  Pancreatitis and Duodenal Perforation as a Complication of an Endoscopically Placed Biliary Stent - Difficulty in Diagnosis.  Gastrointestinal Endoscopy, 1994, 40(3): 365-366.

4. Humar A, Barron P, Radzuik J, Davies J.  The Site of Pancreatic Venous Drainage, Glucose Tolerance, and Insulin Sensitivity.   Clinical and Investigative Medicine, Supp. 1993, 16(4): 881. 

5. Humar A, Tao H, Lum A, Barron P, Rhodes I. and Yazdi H.  CT and Cytological Assessment of Cystic Pancreatic Neoplasms: A Difficult Preoperative Diagnosis. Canadian Association of Radiologists Journal, 1993, 44(5): 359-363.

6. Humar A, Barron P, Sekar A, and Lum A.  Pancreatitis and duodenal perforation as a complication of an endoscopically placed biliary stent - difficulty in diagnosis.  Gastrointestinal Endoscopy, 1994, 40(3): 365-366.

7. Radziuk J, Barron PT, Humar A, Davies J.  Diminished  Sensitivity and  Responsiveness to Insulin with Systemic Pancreatic Venous Drainage.   Diabetologia, 1994, 37:suppl 1, 151.

8. Humar A, Sharpe J, Hollomby D.  Salvage of a Renal Allograft with Renal Vein Occlusion Secondary to Extrinsic Compression.   American Journal of Kidney Diseases, 1996, 28(4): 622.

9. Humar A, Gillingham K, Remucal M, Kerr S, Matas A, Johnson E, Dahms R, Rudy J, Gillingham K, Remacal M.  Chronic Rejection and Donor Recipient Size Disparity.   Journal of American Society of Nephrology, 1996, 7(9), 1913.

10. Johnson E, Gillingham K, Humar A, Matas A.  Effect of Gender Weight on Kidney Allograft Survival and Acute Rejection.   Journal of American Society of Nephrology, 1996, 7(9), 1913.

11.  Johnson E, Remucal M, Pandian K, Gillingham K, Dahms R, Humar A, Matas AJ.   Complications and Risks of Renal Donation.. Journal of American Society of Nephrology, 1996, 7(9): 1913.

12. Johnson E., Canafax DM, Gillingham K, Humar A, Pandian K, Kerr SR, Najarian AJ, Matas AJ.  Effect of Early Cyclosporine Levels on Kidney Allograft Rejection.    Clinical Transplantation, 1997, 11: 552-557.

13.  Humar A, Gillingham K, Johnson E, Matas A.  Effect of Initial Slow Graft Function on Renal Allograft Rejection and Survival.   Clinical Transplantation, 11(6), 623, 1997.

14. Humar A, Matas A.  Kidney Transplantation: a Brief Review.   Frontiers in Bioscience, 1997, 2: 41.

15. Leone J, Humar A, Gruessner R, Sutherland D.  Pancreas Transplantation: Indications, Clinical Management, and Outcomes.  Frontiers in Bioscience. 1997, Vol. 2.

16. Humar A, Gruessner R, Sutherland D.  Living Related Donor Pancreas and Pancreas-kidney Transplantation.   British Medical Bulletin.  1997, Vol. 53(4).

17. Humar A, Gillingham K, Johnson E, Gruessner R, Matas A.  Venous Thromboembolic Complications after Kidney and Kidney-Pancreas Transplant: a Multivariate Analysis.  Transplantation 1998, 65: 229.

18. Humar A, Gillingham K, Johnson E, Gruessner R, Matas A.  The Acutely Ischemic Extremity after Transplant: An Approach to Management.   Surgery 1998, 123(3): 344-350.

19. Humar A, Remucal M, Matas A, Najarian JS.  Kidney transplantation in children younger than 1 year using cyclosporine immunosuppression.    Ann Surg 1998, 228(3): 421-428.

20. Humar A, Grubbs B, Zapzalka D, Nazarian W, Hunter D, Matas A.  Isolated Iliac Artery Stenosis as a Cause of Kidney Graft Dysfunction Posttransplant.    Clinical Transplantation 1998, 12: 406-408.

21. Humar A, Jessurun J, Gruessner, R.  Thrombotic Microangiopathy after Combined Liver Small Bowel Transplant- a first report.   Clinical Transplantation 1998, 12: 600-601.

22. Jiang J, Humar A, Garcia B, Zhong R.  Surgical technique for vascularized ear transplantation in mice.   Microsurgery 1998, 18:  42-46.

23. Humar A, Mauer M, Durand B, Payne W, Sharp H, Gruessner R.  Kidney and liver transplantation from living related and cadaver donors for primary hyperoxaluria type 1.   Pediatric Transplantation 1998, 2(1): 47.

24. Humar A, Sharp H, Payne W, Walsh J, Gruessner R.  Preoperative radiologic assessment of living related liver donors.   Pediatric Transplantation 1998, 2(1): 47.

25. Humar A, Sharp H, Lynch S, Gruessner R.  Living related bowel transplant and cadaver liver/bowel transplant in the pediatric population.   Pediatric Transplantation 1998, 2(1): 47.

26. Gruessner RWG, Sutherland D, Drangstveit M, Wrenshall L, Humar A, Gruessner A.   Mycophenolate Mofetil in Pancreas Transplantation.  Transplantation 1998, 66:318-323.

27. Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL Matas A. Cytomegalovirus Disease Recurrence After Ganciclovir Treatment in Kidney and Kidney-pancreas Transplant Recipients.  Transplantation, 1999, 67(1): 94–7.

28. Humar A, Jesurun J, Sharp H, Gruessner R.  Hemolytic uremic syndrome in small bowel transplant recipients: the first two case reports.  Transplant International 1999, 12:387-390.

29. Johnson EM, Anderson JK, Jacobs C, Suh G, Humar A, Suhr BD, Kerr SR, Matas AJ.  Long-term follow-up of living kidney donors: quality of life after donation.  Transplantation 1999, 67(5): 717-21.

30. Humar A, Hassoun A, Kandaswamy R, Payne WD, Sutherland DER, Matas AJ.  Immunologic factors—the major risk for decreased long-term allograft survival.   Transplantation 1999, 68: 1842-6.

31. Humar A, Gillingham K, Payne WD, Sutherland DER, Dunn D, Matas AJ.  Association between CMV disease and chronic rejection in kidney transplant recipients.   Transplantation 1999, 68: 1879-83.

32. Matas A, Humar A, Payne WD, Gillingham KJ, Dunn DL, Sutherland DE, Najarian JS.  Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection.   Ann Surg 1999, 230:493-8.

33. Humar A, Kerr S, Gillingham K, Matas A.  Features of acute rejection that predict increased risk for chronic rejection.  Transplantation 1999, 68: 1200-3.

34. Matas AJ, Gillingham KJ, Humar A, Dunn DL, Sutherland DER, Najarian JS.  Immunologic and Nonimmunologic Factors: different risks for cadaver and living donor transplantation.  Transplantation 2000, 69(1): 54-58.

35. Humar A, Kandaswamy R, Granger D, Gruessner RW, Gruessner AC, Sutherland DE.  Decreased surgical risks of pancreas transplantation in the modern era.  Ann Surg 2000, 231(2):269-75. 

36. Humar A, Parr E, Drangstveit M, Kandaswamy R, Gruessner A, Sutherland DE.  Steroid withdrawal in pancreas transplant recipients.  Transplantation 2000, 14: 75-78.

37. Humar A, Kandaswamy R, Parr E, Drangstveit MB, Gruessner AC, Sutherland DER.  Prolonged preservation increases surgical complications after pancreas transplants.  Surgery.  2000, 127: 545-51.

38. Humar A, Durand B, Gillingham K, Payne WD, Sutherland DER, Matas AJ.  Living unrelated donors in kidney transplants:  Better long-term results than Non-HLA identical living related donors? . Transplantation 69: 1942-1945, 2000.

39. Humar A, Kandaswamy R, Drangstveit MB, Parr E, Gruessner A, Sutherland DER.  Surgical risks and outcomes of pancreas retransplants.  Surgery.  2000, 127(6): 634-40.

40. Matas AJ, Gillingham K, Payne WD, Humar A, Dunn DL, Sutherland D, Najarian JS.  Should I accept this kidney?  Clin Transplant 2000, 14(1): 90-95.

41. Beebe DS, Carr R, Komanduri V, Humar A, Gruessner R, Belani KG.  Living related liver donor surgery: report of initial anesthesia experience.  Journal of Clinical Anesthesia.  2000, 12: 157-61.

42. Humar A, Payne WD, Sutherland DER, Matas AJ.  Clinical determinants of multiple acute rejection episodes in kidney transplant recipients.  Transplantation 2000, 69(11):2357-60.

43. Humar A, Kandaswamy R, Gruessner RW, Gruessner AC, Sutherland DER.  Optimal timing for a pancreas transplant after kidney transplant. Transplantation. 2000, 70(8):1247-50.

44. Papalois V, Moss A, Gillingham K, Sutherland DER, Matas AJ, Humar A.  Preemptive kidney transplants: an argument against waiting until dialysis.  Transplantation. 2000, 70: 625-31.

45. Humar A, Gillingham K, Matas A. An increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus (CMV) disease. Transplantation 2000, 70(2): 310-314.

46. Moss A, Najarian JS, Sutherland DER, Payne WD, Gruessner RW, Humar A, Kandaswamy R, Gillingham KJ, Dunn DL, Matas AJ.   5,000 kidney transplants--a single-center experience.  Clin Transpl. 2000; 159-71.

47. Wagner C, Beebe DS, Carr RJ, Komanduri V, Humar A, Gruessner RW.  Living Related Liver Transplantation in Infants and Children:  report of anesthetic care and early postoperative morbidity and mortality.  Journal of Clinical Anesthesiology 2000, 12(6): 454-459.

48. Humar A, Key N, Ramcharan T, Payne WD, Sutherland DER, Matas AJ.  Kidney retransplants after initial graft loss to vascular thrombosis.  Clinical Transplant.  2001, 15(1): 6-10.

49. Sutherland DE, Gruessner RW, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS. Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution. Am Surg. 2001, 233(4):463-501.

50. Humar A, Kerr SR, Gillingham KJ, Matas AJ.  Perioperative cardiac morbidity in renal transplant recipients:  incidence and risk factors.  Clinical Transplantation.  2001, 15 (3): 154-8.

51. Humar A, Ramcharan T, Kandaswamy R, Matas AJ, Gruessner RW, Gruessner AC, Sutherland DER.  Pancreas after kidney transplant: a viable alternative to simultaneous pancreas kidney transplant.   American Journal of Surgery  2001 Aug;182(2):155-61.

52. Matas AJ, Payne WD, Sutherland DER, Humar A, Gruessner RW, Kandaswamy R, Dunn DL, Gillingham K, Najarian JS.  2,500 Living Donor Kidney Transplants:  A Single-Center Experience.  Annals of Surgery 2001, 234(2): 149-164.

53. Matas AJ, Ramcharan T, Paraskevas S, Gillingham K, Dunn DL, Gruessner RW, Humar A, Kandaswamy R, Najarian JS, Payne WD and Sutherland DER.  Rapid discontinuation of steroids in living donor kidney transplantation:  a pilot study.  American Journal of Transplantation 2001, 1:  278-283.

54. Matas AJ, Humar A, Kandaswamy R, Payne WD, Gruessner RW, Sutherland DER.  Kidney and pancreas transplantation without a crossmatch in select circumstances - it can be done. Clin Transplant. 2001; 15(4): 236-9. 

55. Gruessner A, Sutherland DER, Dunn DL, Najarian J, Humar A, Kandaswamy R, Gruessner RW.  Pancreas after kidney transplants in posturemic patients with type 1 diabetes mellitus.  J Am Soc Nephrol. 2001;12(11):2490-9.

56. Humar A, Ramcharan T, Sielaff T, Kandaswamy R, Gruessner R, Lake J, Payne WD.  Split liver transplantation for 2 adult recipients: an initial experience.  American Journal of Transplantation 2001; 1(4): 366-72.

57. Ramcharan T, Glessing B, Lake J, Payne WD, Humar A.  Outcome of other organs recovered during in situ split-liver procurements.  Liver Transpl. 2001; 7(10):853-7.

58. Bruce DS, Sollinger HW, Humar A, Sutherland DER, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ.  Multicenter survey of daclizumab induction in simultaneous kidney pancreas transplant recipients.  Transplantation 2001; 72(10): 1637-1643. 

59. Humar A, Ramcharan T, Denny R, Gillingham, K, Payne WD, Matas A.  Are wound complications after a kidney transplant more common with modern immunosuppression?  Transplantation.  2001, 72(12): 1920-1923.

60. Humar A, Arrazola L, Mauer M, Matas AJ, Najarian JS.  Kidney transplantation in young children: should there be a minimum age?  Pediatr Nephrol. 2001;16(12):941-5.

61. Hess D, Sielaff T, Humar A.  Living related liver transplantation for recurrent hepatocellular carcinoma in a normal liver.  Clinical Transplantation.  2002, 16:240-2.

62. Schwarzenberg SJ, Sharp H, Payne WD, Hunter DW, Bjarnason H, Humar A, Weisdorf-Schindele SA, Gruessner RW.  Biliary stricture in living-related donor liver transplantation: management with balloon dilation.  Pediatric Transplantation, 2002, 6(2):132-5.

63. Matas AJ, Humar A, Gillingham K, Payne WD, Gruessner RW, Kandaswamy R, Dunn DL, Najarian JS, Sutherland DER.  Five preventable causes of kidney graft loss in the 1990s:  a single-center analysis.  Kidney International 2002, 62: 704-714.

64. Humar A, Khwaja K, Sielaff TD, Lake JR, Payne WD. Technique of split-liver transplant for two adult recipients. Liver Transpl. 2002, 8(8):725-9.

65. Humar A, Ramcharan T, Kandaswamy R, Gillingham K, Payne WD, Matas AJ.  Risk factors for slow graft function after kidney transplant:  a multivariate analysis.  Clinical Transplantation.  Dec 2002;16(6): 425-9.

66. Humar A. Adult living donor transplants – Which portion of the liver to use?  Liver Trasnplantation. 2003:,9(6): 634-6.

67. Kosari K, Coad JE, Humar A, Sielaff T.  Liver tumors 4.  Thermal fixation: the histopathology of hepatocellular cancer after radiofrequency ablation in liver transplantation.  J Gastrointest Surg. Feb 2003;7(2):259.

68. Paraskevas S, Kandaswamy R, Humar A, Gillingham K, Gruessner RW, Payne WD, Najarian JS, Dunn DL, Sutherland DER, Matas AJ.  Predicting long-term kidney survival: can new trials be performed?  Transplantation.  Apr 2003,;75(8):1256-9.

69. Matas AJ, Humar A.  Why study kidney transplant risk factors?  Transplantation.  Feb 2003;75(3):266-7.

70. Khwaja K, Wijkstrom M, Gruessner AC, Noreen H, Sutherland DER, Humar A, Kandaswamy R, Gruessner RW.  Pancreas transplantation in crossmatch-positive recipients. Clin Transplant. Jun 2003, 17(3): 242-48.

71. Khwaja K, Humar A, Najarian JS.  Kidney transplants for children under 1 year of age – a single-center experience.  Pediatric Transplant.  Jun 2003;7(3):163-7.

72. Gaston R, Alveranga D, Becker B, Distant D, Held P, Bragg-Gresham J, Humar A, Ting A, Wynn J, Leichtman A.  Kidney and pancreas transplantation.  SRTR Report on the State of Transplantation.  American Journal of Transplantation.  2003, Vol. 3, Supplement 4: 64-77.

73. Coad J, Kosari K, Humar A, Sielaff T.  Radiofrequency ablation causes ‘thermal fixation’ of hepatocellular carcinoma: a post-liver transplant histopathologic study.”  Clin. Transplant.  Aug 2003, 17(4): 377-84.

74. Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, Heaton N, Humar A, Fung JF.  Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis. 2003 Nov 15;188(10):1412-20.

75. Humar A. Donor and recipient outcomes after adult living donor liver transplantation.  Liver Transpl. 2003 Oct;9(10 Suppl 2):S42-4.

76. Humar A, Khwaja K, Ramcharan T, Asolati M, Kandaswamy R, Gruessner RW, Sutherland DE, Gruessner AC.  Chronic rejection: the next major challenge for pancreas transplant recipients.  Transplantation. 2003 Sep 27;76(6):918-23.

77. Kandaswamy R, Humar A, Khwaja K, Asolati M, Harmon J, Gillingham K, Matas AJ.  Study 1:  A prospective, randomized study of cyclosporine-mycophenolate mofetil versus tacrolimus-sirolimus with rapid discontinuation of prednisone.  Transplantation Reviews.  2003, 17(4).

78. Humar A, Denny R, Matas AJ, Najarian JS.  Graft and quality of life outcomes in older recipients of a kidney transplant.  Experimental and Clinical Transplantation: Official Journal of the Middle East Society for Organ Transplantation.  2003, 1(2):69-72.

79. Linden BC, Humar A, Sielaff TD.  Laparoscopic stapled left lateral segment liver resection – technique and results.  J Gastrointest Surg.  2003, Sep-Oct; 7(6):777-82.

80. Gaston R, Alveranga D, Becker B, Distant D, Held P, Bragg-Gresham J, Humar A, Ting A, Wynn J, Leichtman A.  Kidney and pancreas transplantation.  SRTR Report on the State of Transplantation.  Hypertension , Dialysis, and Clinical Nephrology.  http://www.hdcn.com, April 24, 2003.

81. Humar A, Khwaja K, Sielaff T, Lake J, Payne WD.  Split-liver transplants for 2 adult recipients: technique of preservation of the vena cava with the right lobe graft.  Liver Transplantation.  2004 Jan 10(1): 153-55.

82. Humar A, Khwaja K, Glessing B, Larson E, Asolati M, Durand B, Lake J, Payne WD.  Regionwide sharing for status 1 liver patients - beneficial impact on waiting time and pre- and posttransplant survival.   Liver Transpl. 2004 May;10(5):661-5.

83. Tan M, Kandaswamy R, Sutherland DE, Gruessner RW, Gruessner AC, Humar A. Risk factors and impact of delayed graft function after pancreas transplants. Am J Transplant. 2004 May;4(5):758-62.

84. Humar A, Ramcharan T, Kandaswamy R, Gruessner RW, Gruessner AC, Sutherland DER.  The impact of donor obesity on outcomes after cadaver pancreas transplants. Am J Transplant. 2004 Apr;4(4):605-10.

85. Humar A, Kosari K, Sielaff TD, Glessing B, Gomes M, Dietz C, Rosen G, Lake J, Payne WD.  Liver regeneration after adult living donor and deceased donor split-liver transplants.  Liver Transpl. 2004 Mar;10(3):374-8.

86. Khwaja K, Asolati M, Harmon J, Melancon JK, Dunn T, Gillingham K, Kandaswamy R, Humar A, Gruessner R, Payne W, Najarian J, Dunn D, Sutherland D, Matas AJ.  Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant. 2004;4(6):980-7.

87. Matas AJ, Kandaswamy R, Humar A, Payne WD, Dunn DL, Najarian JS, Gruessner RW, Gillingham KJ, McHugh LE, Sutherland DER.  Long-term immunosuppression, without maintenance prednisone, after kidney transplantation.  Ann Surg Sept 2004, 240(3):510-6, discussion 516-7.

88. Humar A, Ramcharan T, Kandaswamy R, Gruessner RW, Gruessner AC, Sutherland DE. Technical failures after pancreas transplants: why grafts fail and the risk factors – a multivariate analysis.  Transplantation. 2004 Oct 27;78(8):1188-92. 

89. Ashrani AA, Reding MT, Shet A, Osip J, Humar A, Lake JR, Key NS.  Successful liver transplantation in a patient with severe haemophilia A and a high-titre factor VIII inhibitor.  Haemophilia. 2004 Nov;10(6):735-7

90. Khwaja K, Asolati M, Harmon JV, Melancon JK, Dunn TB, Gillingham KJ, Kandaswamy R, Humar A, Gruessner RW, Payne WD, Najarian JS, Dunn DL, Sutherland DE, Matas AJ.  Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation. 2004 Nov 15;78(9):1397-9.

91. Humar A, Horn K, Kalis A, Glessing B, Payne WD, Lake J.  Living donor and split-liver transplants in Hepatitis C recipients: does liver regeneration increase the risk for recurrence?  Am J Transplant. 2005 Feb;5(2):399-405.

92. Feng S, Humar A, Pomfret E, Fishbein T, Gaber O.  Surgical Challenges in Transplantation: The Fourth Annual American Society of Transplant Surgeons' State-of-the-Art Winter Symposium.  Am J Transplant. 2005 Mar;5(3):428-435.

93. Ortiz J, Reich DJ, Manzarbeitia C, Humar A.  Successful re-use of liver allografts: three case reports and a review of the UNOS database.  Am J Transplant. 2005 Jan;5(1):189-92

94. Humar A, Carolan E, Ibrahim H, Horn K, Larson E, Glessing B, Kandaswamy R, Gruessner RW, Lake J, Payne WD.  A Comparison of Surgical Outcomes and Quality of Life Surveys in Right Lobe vs. Left Lateral Segment Liver Donors.  Am J Transplant. 2005 Apr;5(4):805-9.

95. Nath DS, Gruessner A, Kandaswamy R, Gruessner RW, Sutherland DE, Humar A. Late anastomotic leaks in pancreas transplant recipients - clinical characteristics and predisposing factors.  Clin Transplant. 2005 Apr;19(2):220-4.

96. Banton KL, D’Cunha J, Laudi N, Flynn C, Hammerschmidt D, Humar A, Sielaff T.  Postoperative severe microangiopathic hemolytic anemia associated with a giant hepatic cavernous hemangioma.  J Gastrointest Surg. 2005 May-Jun, 9(5):679-85.

97. Gruessner RW, Kandaswamy R, Humar A, Gruessner AC, Sutherland DER.  Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation.  Transplantation. 2005 May, 79(9): 1184-9.

98. Kandaswamy R, Melancon JK, Dunn T, Tan M, Casingal V, Humar A, Payne WD, Gruessner RW, Dunn DL, Najarian JS, Sutherland DER, Gillingham KJ, Matas AJ.  A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients – an interim analysis.  Am J Transplant. 2005 Jun, 5(6): 1529-36.

99. Matas AJ, Kandaswamy R, Gillingham K, McHugh L, Ibrahim H, Kasiki B, Humar A.  Prednisone-free maintenance immunosuppression – a 5 year experience,   American Journal of Transplantation.  2005 Oct, 5(10): 2473-8.

100. Parkaskevas S, Coad JE, Kandaswamy R, Humar A, Sutherland DER, Gruessner RW. Posttransplant lymphoproliferative disorder in pancreas transplantation: a single-center experience.  Transplantation. 2005 Sept, 80(5):613-22.

101. Humar A, Matas AJ. Surgical complications after kidney transplantation.  Semin Dial. 2005 Nov-Dec, 18(6):505-10.

102. Nath D, Gruessner AC, Kandaswamy R, Gruessner RW, Sutherland DER,  Humar A. Outcomes of pancreas transplants for patients with type 2 diabetes mellitus. Clin Transplant. 2005 Dec,19(6):792-7.

103. Ibrahim H, Rogers T, Casingal V, Sturdevant M, Tan M, Humar A, Gillingham K, Matas A.  Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol.  Transplantation 2006 21(2): 214-219.

104. Ragni M, Belle SH, Im K, Fung J, Neff G, Roland M, Stock P, Heaton N, Humar A.Liver transplantation in HIV-seropositive individuals.  Ann Intern Med.  2006 Feb 7, 144(3):223.

105. Nath D, Kalis A, Nelson S, Payne WD, Lake JR, Humar A.  Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy.  Clin Transplant.  2006 Mar-Apr, 20(2):206-10.

106. Ragni M, Fung J, Neff G, Roland M, Heaton N, Humar A.  Letter to the Editor: Liver Transplantation in HIV-Seropositive Individuals.  JAMA 2006 144(3): 223.

107. Humar A, Hebert D, Davies HD, Humar A, Stephens D, O’Doherty B, Allen U.  A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.  Transplantation.  2006, Mar;81(6):856-61.

108. Humar A. How safe and useful are left-lobe grafts in living donor liver transplantation?  Nat Clin Pract Gastroenterol Hepatol. 2006 Sep;3(9):486-487.

109. Paraskevas S, Kandaswamy R, Humar A, Gillingham KJ, Gruessner RW, Payne WD, Najarian JS, Sutherland DE, Matas AJ.  Risk factors for rising creatinine in renal allografts with 1 and 3 yr survival.  Clin Transplant. 2006 Nov-Dec;20(6):667-72.

110. Humar A,  Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, Lake J.  Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and posttransplant diabetes.  Clin Transplant. 2007 Jul-Aug;21(4):526-31

111. Humar A.  Pancreas Donors. Curr Opin Organ Transplant.  2007, 12:73-76.

112. Adrogue H, Matas AJ, McGlennon RC, Key NS, Gruessner AC, Gruesser RW, Humar A, Sutherland DER, Kandaswamy R.  Do inherited hypercoagulable states play a role in thrombotic events affecting kidney/pancreas transplant recipients?  Clin Transplantation.  2007 Jan-Feb, 21:32-37.

113. Humar A, Gillingham K, Kandaswamy R, Payne W, Matas A.  Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode.  Am J Transplant. 2007 Aug;7(8):1948-53.

114. Nagral A, Nabi F, Humar A, Nagral S, Doctor N, Khubchandani SR, Amdekar YK.  Reversal of severe hepato-pulmonary syndrome in congenital hepatic fibrosis after living-related liver transplantation.  Indian J Gastroenterol. 2007 Mar-Apr;26(2):88-9.

115. Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.  Transplantation. 2007 Mar 27;83(6):722-6.

116. Abbud-Filho M, Adams PL, Alberú J, Cardella C, Chapman J, Cochat P, Cosio F, Danovitch G, Davis C, Gaston RS, Humar A, Hunsicker LG, Josephson MA, Kasiske B, Kirste G, Leichtman A, Munn S, Obrador GT, Tibell A, Wadström J, Zeier M, Delmonico FL.  A report of the Lisbon Conference on the care of the kidney transplant recipient.  Transplantation. 2007 Apr 27; 83(8 Suppl):S1-22.

117.  Chavers B, Najarian J, Humar A.  Kidney transplantation in infants and small children. Pediatric Transplantation.   2007 Nov; 11(7):702-8.

118.  Wang S, Sturdevant M, Kandaswamy R, Gruessner R, Sutherland DER, Humar A. Technical failure of the pancreas after SPK transplant – are these patients good candidates for later pancreas transplants.  Clinical Transplantation.  Accepted

119.  Matas A, Kasiske B, Gillingham K, Humar A, Ibrahim H, Payne W, Gruessner R, Dunn T, Sutherland DER, Najarian JS, Kandaswamy.  Posttransplant Diabetes Mellitus and acute rejection: impact on kidney transplant outcome.  Transplantation. Accepted

Top of page

Articles not peer-reviewed

1. Humar A, Mauer M, Durand B, Payne WD, Sharp H, Gruessner RW.  Kidney and liver transplantation from living related and cadaver donors for primary hyperoxyluria type 1.   Pediatric Transplantation 1998, 2(1): 47.

2. Humar A, Sharp H, Payne WD, Walsh J, Gruessner RW.  Preoperative radiologic assessment of living related liver donors.   Pediatric Transplantation 1998, 2(1): 47.

3. Humar A, Sharp H, Lynch S, Gruessner RW.  Living related bowel transplant and cadaver liver/bowel transplant in the pediatric population.   Pediatric Transplantation 1998, 2(1): 47.

4. Barron, PT, Humar A., Davies, J, Radziuk, J.  Insulin sensitivity and glucose tolerance when pancreatic venous drainage is diverted to the systemic circulation in pancreas transplantation.  Transplantation Proceedings, 1994, 26(2): 487-9.

5. Humar A, Kerr S, Hassoun A, Granger D, Suhr B, Gillingham D, Matas A.  Features of acute rejection that predict increased risk for chronic rejection. Transplantation Proceedings 1999, 31(1-2):1302-1303.

6. Humar A, Harmon J, Gruessner A, Kandaswamy R, Granger D, Zhang K, Drangstveit MB, Sutherland DER, Gruessner RWG.  Surgical complications requiring early relaparotomy after pancreas (Pa) transplantation (Tx):  comparison of the FK and CsA era.   Transplantation Proceedings 1999, 31:606-607.

7. Humar A, Kerr S, Hassoun A, Granger D, Suhr B, Matas AJ.  The association between acute rejection and chronic rejection in kidney transplantation.  Transplantation Proceedings 1999, 31(1-2): 1302-3.

8. Kandaswamy R, Humar A, Gruessner AC, Harmon J, Granger D, Lynch S, Sutherland DER, Gruessner RW.  Vascular graft thrombosis after pancreas transplantation:  comparison of the FK and CsA era.  Transplantation Proceedings 31:602-603, 1999.

9. Arrazola L, Sozen H, Humar A, Papalois V, Uknis M, Matas A.J.  Kidney transplant using pediatric donors – effect on long-term graft and patient survival.  Transplantation Proceedings 2000, 32(7): 1839.

10. Arrazola L, Sozen H, Humar A, Uknis M, Papalois V, Matas AJ.  Death with function:  the next major hurdle.  Transplant Proceedings 2000, 32(7):  1832.

11. Arrazola L, Sozen H, Humar A, Papalois V, Uknis M, Matas AJ.  Both immunologic and nonimmunologic factors are risks for long-term graft survival – a multivariate analysis.  Transplant Proceedings 2000, 32(7): 1831.

12. Arrazola L, Sozen H, Humar A, Papalois V, Uknis M, Matas AJ.  Increasing incidence of steroid resistant rejection in kidney transplantation.  Transplant Proceedings 2000, 32(7): 1767.

13. Sutherland DER, Gruessner RW, Humar A, Kandaswamy R, Najarian, JS, Dunn DL.  Pretransplant immunosuppression for pancreas transplants alone in nonuremic diabetic recipients.  Transplantation Proceedings.  2001, 33(1-2): 1656-8.

14. Kandaswamy R, Gillingham K, Humar A, Payne WD, Dunn DL, Sutherland DER, Najarian JS, Matas AJ.  Impact of HLA-ABDR match on chronic rejection in kidney transplants.  Transplantation Proceedings.  2001 Feb-Mar; 33(1-2): 1292.

15. Kandaswamy R, Sutherland DERS, Humar A, Payns WD, Gruessner RW, Matas AJ.  Transplantation without a final crossmatch – it can be done.  Transplantation Proceedings.  2001, 33(1-2): 1234.

16. Kandaswamy R, Humar A, Payne WD, Dunn DL, Sutherland DER, Matas AJ.  Risk factors for kidney transplant acute rejection:  a multivariate analysis.  Transplantation Proceedings.  2001, 33(1-2): 1112.

17. Gruessner RW, Sutherland DER, Parr E, Humar A, Gruessner AC.  A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transplant Proc. 2001 Feb-Mar 2001;33(1-2):1663-4.

18. Sutherland DER, Gruessner RW, Kandaswamy R, Humar A, Hering B, Gruessner RW.  Beta-cell replacement therapy (pancreas and islet transplantation) for treatment of diabetes mellitus: an integrated approach.  Transplant Proceedings.  Jul-Aug 2004, 36(6):1697-9.

19. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc. 2005 Mar;37(2):934-6

20. Jie T, Matas AJ, Gillingham KJ, Sutherland DE, Dunn DL, Humar A.  Mycobacterial infections after kidney transplant. Transplant Proc. 2005 Mar;37(2):937-9.

Articles Submitted for Publication

1. Matas AJ, Humar A, Gillingham K, Payne WD, Gruessner RW, Kandaswamy R, Dunn DL, Najarian JS, Sutherland DER.  Improving long-term kidney allograft survival – where do we go from here?  Submitted to Kidney International.

2. J van Burik J, Burns L, Dunitz J, Sutherland DER, Humar A, Dunn DL, Weisdorf D.  Cryptococcal infection following transplantation with or without calcineurin inhibitors used for immunosuppression.  Submitted to American Journal of Transplantation. 

Top of page

BOOK CHAPTERS:

1. Humar A., Gruessner, R.  Critical Care of the Liver Transplant Recipient.   Intensive Care Medicine 4th Edition.  Editors Rippe, Irwin, Fink, Cerra.  Lippincott-Raven, 1998.

2. Humar A, Matas A.  Immunosuppression: Use in transplantation.   Encyclopedia of Life Sciences.  Macmillan Ref Ltd. 1999.

3. Humar A., Dunn, DL.  Critical Care of Organ Transplant Recipients:  Introduction..  Manual of Intensive Care Medicine, 3rd edition. Editors Irwin & Rippe.  Lippincott, Williams & Wilkins. 2000.

4. Humar A, Dunn DL.  Critical Care of the Cadaver Organ Donor.  Manual of Intensive Care Medicine 3rd edition. Editors Irwin & Rippe.  Lippincott, Williams & Wilkins. 2000.

5. Humar A, Dunn DL.  Critical Care of the Kidney Transplant Recipient.  Manual of Intensive Care Medicine, 3rd edition. Editors Irwin & Rippe.  Lippincott, Williams & Wilkins. 2000.

6. Humar A, Dunn DL.  Critical Care of the Pancreas Transplant Recipient.  Manual of Intensive Care Medicine3rd edition. Editors Irwin & Rippe.  Lippincott, Williams & Wilkins. 2000.

7. Humar A, Dunn DL.  Critical Care of the Liver Transplant Recipient.  Manual of Intensive Care Medicine, 3rd edition. Editors Irwin & Rippe.  Lippincott, Williams & Wilkins. 2000.

8. Humar A, Dunn DL.  Critical Care of the Heart, Heart-Lung, And Lung Transplant Recipient.  Manual of Intensive Care Medicine, 3rd edition. Editors Irwin & Rippe.  Lippincott, Williams & Wilkins. 2000.

9. Humar A, Dunn DL.  Rejection, Infection, and Malignancy in Solid Organ Transplant Recipients.    Manual of Intensive Care Medicine, 3rd edition. Editors Irwin & Rippe.  Lippincott, Williams & Wilkins. 2000.

10. Humar A, Matas A.  New Immunosuppressive Drugs.  Transplantation Surgery. Editors Hakim & Danovitch. Springer 2001.

11. Humar A, Gruessner RW, WD Payne.  Critical Care of the Liver Transplant Recipient.   Intensive Care Medicine 5th Edition.  Editors Rippe, Irwin, Fink, Cerra.  Lippincott-Raven, 2002.

12. Humar A, Matas AJ.  Immunosuppression:  use in transplantation.  Encyclopedia of Life Sciences.  2001 Nature Publishing Group, www.els.net

13. Kennedy M, Humar A, Matas A.  Immunosuppression in solid organ transplantation.     Intensive Care Medicine 5th Edition.  Editors Rippe, Irwin, Fink, Cerra.  Lippincott-Raven, 2002.

14. Khwaja K, Humar A.  Pretransplant Evaluation and Preparation.  Pancreas Transplantation.  Editors Gruesser RW, Sutherland DER.  Springer-Verlag. 2002.

15. Humar A, Humar A.  Risks and Epidemology of Infections after Pancreas or Kidney-Pancreas Transplantation.  Transplant Infections, 2nd edition.  Editors Bowden, Ljungman, and Paya.  Lippincott Williams and Wilkins, 2003.

16. R Kandaswamy, Humar A.  Manual of Kidney Transplant Medical Care.  Surgical Procedures.  Fairview-University Medical Center Publications.  2003.

17. Humar A.  Manual of Kidney Transplant Medical Care.  Early Postoperative Management.  Fairview-University Medical Center Publications.  2003

18. A Humar, AJ Matas.  The Association between Acute and Chronic Rejection.  Organ Transplantation 2nd Edition.  Editors Stuart, Abecassis, and Kaufman.  Landes Bioscience, 2003.

19. Humar A, Dunn D.  Transplantation.  Principles of Surgery, 8th edition.  Editor Schwartz.  2004

20. Humar A, Payne WD.  Critical Care of Liver and Intestinal Transplant Recipients.  Irwin and Rippe’s Intensive Care Medicine, 6th ed.  Editors Rippe, Irwin, Fink, Cerra.  Lippincott-Raven.  In Press.  2007

Top of page

BOOKS:

1. Humar A, editor.  Manual of Liver Transplant Medical Care.  Fairview-University Medical Center Publications.  2001.

2. Humar A, Matas AJ, Payne WD, eds.  Atlas of Organ Transplants.  Springer Verlag.  2006.

Top of page

ABSTRACT PRESENTATIONS:

1. The history of acute peritoneal Dialysis at CHEO. Humar A, Bass J, CHEO Resident’s Research Day, 1991. (Best presentation award.)

2. Fibromatosis in infancy and childhood: the spectrum.  Humar A, Chou S, Carpenter B. CHEO Resident’s Research Day, Ottawa, 1991.

3. Fibromatosis in infancy and childhood: the spectrum. Humar A, Chou S, Carpenter B.  Annual meeting of Canadian Association of Pediatric Surgeons, Quebec City, 1991 (Best resident presentation award.)

4. Cystic tumors of the pancreas: clinical and radiological observations.  Humar A, Barron PT, Mimeault R, Sekar A.  96th. Annual meeting of the Canadian Association of Clinical Surgeons, Ottawa, 1992.

5. Diversion of pancreatic venous drainage to systemic circulation and its effect on insulin sensitivity in dogs.  Humar A, Barron PT, Radziuk J, Davies J.  University of Ottawa Collins Surgical Day, Ottawa, 1992. (Best presentation award.)

6. Diversion of pancreatic venous drainage to systemic circulation and its effect on insulin sensitivity in dogs.  Humar A, Barron PT, Radziuk J, Davies J.  CAGS Resident’s Research Conference, St. Adele, Quebec, 1992.

7. Insulin sensitivity and glucose tolerance following diversion of pancreatic venous drainage to systemic circulation.  Barron PT, Humar A, Radziuk J, Davies J.  Fourth International Congress on Pancreas and Islet Cell Transplantation, Amsterdam, Netherlands, 1993.

8. The role of CT and FNA in differentiating cystic neoplasms of the pancreas.  Humar A, Barron PT, Yazdi H, Rhodes I, Tao H, Lum A. University of Ottawa Collins Surgical Day, Ottawa, 1993. (Best presentation award.)

9. The role of CT and FNA in differentiating cystic neoplasms of the pancreas.  Humar A, Barron PT, Yazdi H, Rhodes I, Tao H, Lum A. CAGS Resident’s Research Conference, Banff, 1993.

10. The role of CT and FNA in differentiating cystic neoplasms of the pancreas.  Humar A, Barron PT, Yazdi H, Rhodes I, Tao H, Lum A. CAGS Annual Meeting, Vancouver, 1993.

11. Absorbable polyglyconate suture for hemodialysis access surgery. Humar A and J. Wellington, University of Ottawa Vascular Day, Ottawa, 1993.

12. Insulin sensitivity and glucose tolerance following transportation of pancreas venous drainage to systemic circulation. Humar A, Barron PT, Radziuk J, Davies J. Canadian Transplantation Society Meeting, Whistler, B. C., Sept. 1993.  (poster).

13. Venous gangrene.  Humar A, Lorimer J.  Annual Meeting of the Canadian Association of University Surgeons, London, Ontario. May 1994.

14. Exercise testing as a predictor of mortality and morbidity after thoracotomy.  Humar A, Loewen G, Takita H, Antkowiak J. Annual Meeting of the Canadian Association of University Surgeons, London, Ontario. May 1994.

15. Exercise tolerance as a predictor of mortality and morbidity after thoracotomy.  Humar A, Loewen G, Takita H, Antkowiak J. Collins Surgical Day, Ottawa, 1994. (Best Presentation Award).

16. Diminished sensitivity and responsiveness to insulin with systemic pancreatic venous drainage.  Radziuk J, Barron PT, Humar A, Davies J. European Association for the Study of Diabetes. Dusseldorf, Aug. 1994.

17. Systemic pancreatic venous drainage induces a decreased sensitivity and responsiveness to insulin in dogs. Radziuk J, Barron PT, Humar A, Davies J. 15th. International Diabetes Federation Congress. Kobe, Japan. Nov. 1994.

18. Attempt at development of a suicide gene directed against P53.  Humar A, J. Bell, Cancer Research Group, University of Ottawa.  Presented at General Surgery Review Day, April 1995.

19. Effect of initial slow graft function on renal allograft rejection and survival.  Humar A, Gillingham K, Johnson E, Matas AJ.  American Society of Nephrology.  New Orleans.  Nov. 1996. (poster) (Blue ribbon abstract).

20. Chronic rejection and donor recipient size disparity.  Johnson E, Dahms R, Rudy J, Humar A, Gillingham K, Remucal M, Kerr S, Matas AJ. American Society of Nephrology.  New Orleans.  Nov. 1996. (poster)

21. Effect of gender weight on kidney allograft survival and acute rejection.  Johnson E, Gillingham K, Humar A, Matas AJ. American Society of Nephrology.  New Orleans.  Nov. 1996. (poster).

22. Complications and risks of renal donation. Johnson E, Remucal M, Pandian K, Gillingham K, Dahms R, Humar A, Matas AJ.  American Society of Nephrology.  New Orleans.  Nov. 1996. (poster).

23. Recurrent CMV disease after ganciclovir treatment in kidney and kidney-pancreas transplant recipients.  Humar A, Uknis M, Carlone-Jambor C, Gillingham K, Dunn DL, Matas AJ. American Society of Transplant Surgeons. Chicago, May 1997. (poster).

24. Venous thromboembolic complications after kidney and kidney-pancreas transplant: a multivariate analysis.  Humar A, Gillingham K, Johnson E, Gruessner RW, Matas AJ.  ASTP.  Chicago, May 1997. (poster).

25. The disappearing face of acute rejection. Humar A, Gillingham K, Johnson E, Matas AJ.  ASTP.  Chicago, May 1997. (poster).

26. Effect of initial slow graft function on renal allograft rejection and survival.  Humar A, Gillingham K, Johnson E, Matas AJ.  American Society of Transplant Surgeons. Chicago, May 1997(podium- Young investigator’s award)

27. Recurrent CMV disease after ganciclovir treatment.  Humar A, Uknis M, Carlone-Jambor C, Gillingham K, Dunn DL, Matas AJ. American Society of Nephrology. San Antonio Nov 1997. (podium).

28. Kidney transplantation in children under the age of 1 using cyclosporine immunosuppression.  Humar A, Nevins T, Remucal M, Matas AJ.  American Surgical Association.  West Pam Beach, April 1997.  (podium).

29. Features of acute rejection that predict increased risk for chronic rejection.  Humar A, Kerr S, Hassoun A, Granger D, Suhr B, Gillingham K, Matas AJ.  Annual Scientific Meeting of the American Society of Transplant Surgeons.  Chicago, May 1998.  (podium). (Young Investigators Award).

30. Surgical complications requiring early relaparotomy after pancreas (Pa) transplantation (Tx):  comparison of the FK and CsA era.  Humar A, Harmon J, Gruessner AC, Kandaswamy R, Granger D, Zhang K, Drangstveit MB, Sutherland DER, Gruessner RW.  Annual Scientific Meeting of the American Society of Transplant Surgeons.  Chicago, May 1998.  (podium).

31. Vascular graft thrombosis after pancreas transplantation:  comparison of the FK and CsA era.  Kandaswamy R, Humar A, Gruessner AC, Harmon J, Granger D, Lynch S, Sutherland DER, Gruessner RW.  Annual Scientific Meeting of the American Society of Transplant Surgeons.  Chicago, May 1998.  (poster).

32. What is the ideal intervention for ureteral obstructions/stricture?  Granger D, Lehmann SL, Humar A, Hunter DW, Matas AJ.  Annual Scientific Meeting of the American Society of Transplant Surgeons.  Chicago, May 1998.  (podium).

33. Simultaneous pancreas-kidney transplantation (SPK):  living related donor vs. cadaver donor.  Humar A, Gruessner AC, Kandaswamy R, Harmon J, Granger D, Zhang K, Lynch S, Sutherland DER, Gruessner RW.  Annual Scientific Meeting of the American Society of Transplant Surgeons.  Chicago, May 1998.  (poster).

34. Perioperative cardiac morbidity in renal transplant recipients:  incidence and risk factors.  Kerr SR, Humar A, Granger D, Suhr BJ, Gillingham K, Matas AJ.  American Society of Transplant Physicians 17th Annual Meeting.  Chicago, May 1998.  (podium).

35. Kidney and liver transplantation from living related and cadaver donors for primary hyperoxaluria type 1.  Humar A, Mauer M, Durand B, Payne WD, Sharp H, Gruessner RW.  3rd International Congress on Pediatric Transplantation.  Boston, July 1998.  (poster).

36. Preoperative radiologic assessment of living related liver donors.  Humar A, Sharp H, Payne WD, Walsh J, Gruessner RW.  3rd International Congress on Pediatric Transplantation.  Boston, July 1998.  (poster).

37. Living related bowel transplant and cadaver liver/bowel transplant in the pediatric population.  Humar A, Sharp H, Lynch S, Gruessner RW.  3rd International Congress on Pediatric Transplantation.  Boston, July 1998.  (poster). 

38. Kidney transplantation in children ? 1 using cyclosporine immunosuppression.  Humar A, Nevins T, Kashtan C, Mauer M, Chavers B, Durand B, Remucal M, Matas AJ, Najarian JS. 3rd International Congress on Pediatric Transplantation.  Boston, July 1998.  (podium).  (Young Investigators Award).

39. Features of acute rejection that predict increased risk for chronic rejection.  Humar A, Kerr S, Hassoun A, Granger D, Suhr B, Gillingham K, Matas AJ.  XVII World Congress of the International Transplantation Society. Montreal, Canada, July 1998.  (podium). (Travelling Award).

40. Surgical complications requiring early relaparotomy after pancreas (Pa) transplantation (Tx):  comparison of the FK and CsA era.  Humar A, Harmon J, Gruessner AC, Kandaswamy R, Granger D, Zhang K, Drangstveit MB, Sutherland DER, Gruessner RW. XVII World Congress of the International Transplantation Society. Montreal, Canada, July 1998.  (poster).

41. Vascular graft thrombosis after pancreas transplantation:  comparison of the FK and CsA era.  Kandaswamy R, Humar A, Gruessner AC, Harmon J, Granger D, Lynch S, Sutherland DER, Gruessner RW. XVII World Congress of the International Transplantation Society. Montreal, Canada, July 1998.  (poster).

42. Recurrent CMV disease in kidney and kidney-pancreas transplant recipients after ganciclovir treatment.  Humar A, Uknis M, Carlone-Jambor C, Gillingham K, Dunn DL, Matas AJ. XVII World Congress of the International Transplantation Society. Montreal, Canada, July 1998. (poster).

43. The questionable importance of nonimmunologic risk factors in long-term graft survival.  Humar A, Hassoun A, Kandaswamy R, Matas AJ.  ASN 31st Annual Meeting & Scientific Exposition.  Philadelphia, October 1998.  (poster).

44. Both immunologic and nonimmunologic factors are risks for long-term graft survival—a multivariate analysis.  Matas AJ, Humar A, Gillingham K.  ASN 31st Annual Meeting & Scientific Exposition.  Philadelphia, October 1998.  (podium & poster).

45. The questionable importance of nonimmunologic risk factors in long-term graft survival.  Humar A, Hassoun A, Kandaswamy R, Matas AJ.  AST 18th Annual Meeting.  Chicago, May 1999.  (podium).

46. Decreased acute kidney transplant rejection is associated with decreased chronic rejection.  Matas AJ, Gillingham K, Humar A, Dunn DL, Payne WD, Sutherland DER, Najarian JS.  AST 18th Annual Meeting.  Chicago, May 1999.  (poster).

47. Determinants of recurrent acute rejection in kidney transplant recipients.  Humar A, Moss A, Suhr B, Gillingham K, Matas AJ.  AST 18th Annual Meeting.  Chicago, May 1999.  (poster).

48. Cadaver donors greater than age 55:  Which kidneys to use?  Humar A, Arrazola L, Kerr S, Gillingham K, Matas AJ.  AST 18th Annual Meeting.  Chicago, May 1999.  (poster).

49. The association between CMV injection and chronic rejection in kidney transplant recipients.  Humar A, Preito M, Kerr S, Gillingham K, Dunn DL, Matas AJ.  AST 18th Annual Meeting.  Chicago, May 1999.  (podium).

50. Intraabdominal injections after pancreas transplantation:  Recent improvements in incidence and outcome.  Humar A, Gruessner AC, Harmon J, Kandaswamy R, Granger D, Drangstveit MB, Lynch S, Sutherland DER.  AST 18th Annual Meeting.   Chicago, May 1999.  (poster)

51. Pancreatitis after pancreas transplants:  risk factors and consequences.  Humar A, Hassoun A, Kandaswamy R, Parr E, Chmielewski B, Gruessner AC, Sutherland DER.  AST 18th Annual Meeting.  Chicago, May 1999.  (poster).

52. Pancreas retransplants:  surgical risks and outcome.  Humar A, Kandaswamy R, Hassoun A, Drangstveit MB, Durand B, Gruessner AC, Sutherland DER.  AST 18th Annual Meeting.  Chicago, May 1999.  (poster).

53. Kidney and liver transplantation from living related and cadaver donors for primary hyperoxyluria Type I.  Humar A, Mauer M, Durand B, Payne WD, Sharp H, Gruessner RW.  AST 18th Annual Meeting.  Chicago, May 1999.  (poster).

54. Preoperative radiologic assessment of living related liver donors.  Humar A, Sharp H, Payne WD, Walsh J, Gruessner RW.  AST 18th Annual Meeting.  Chicago, May 1999.  (poster).

55. Gender discrepancy in high-risk pancreas (PA) transplant (TX) recipients.  Gruessner AC, Humar A, Sutherland DER.  AST 18th Annual Meeting.  Chicago, May 1999.  (podium).

56. The low incidence of PTLD after pancreas and simultaneous kidney-pancreas transplant.  Hassoun A, Humar A, Kandaswamy R, Long A, Manivel C, Drangstveit MB, Matas AJ, Gruessner RW, Sutherland DER.  AST 18th Annual Meeting.  Chicago, May 1999.  (podium).

57. Steroid withdrawal in pancreas transplant recipients.  Humar A, Parr E, Drangstveit MB, Gruessner AC, Sutherland DER.  AST 18th Annual Meeting.  Chicago, May 1999.  (podium).

58. Death with function (DWF):  the next major hurdle.  Arrazola L, Prieto M, Moss A, Humar A, Matas AJ.  AST 18th Annual Meeting.  Chicago, May 1999.  (podium).

59. Multicenter retrospective analysis of simultaneous kidney pancreas transplant recipients receiving daclizumab induction. Sollinger HW, Bruce DS, Humar A, Sutherland DER, et al.   ASTS 25th Annual Meeting.  Chicago, May 1999.  (podium)

60. An increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus (CMV) disease.  Humar A, Arrazola L, Gillingham K, Matas AJ.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (podium).

61. Optimal timing for a pancreas transplant after a successful kidney transplant.  Humar A, Kandaswamy R, Hassoun A, Drangstveit MB, et al.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (podium) (plenary session).

62. Prolonged preservation time increases the incidence of surgical complications after pancreas transplant. Kandaswamy R, Hassoun A, Parr E, Humar A.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (podium).

63. Kidney transplant using pediatric donors—effect on long term graft and patient survival rates.  Arrazola L, Humar A, Sozen H, Moss A, et al.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (podium).

64. Preemptive transplants in renal failure:  An argument for not waiting until dialysis.  Humar A, Moss A, Gillingham K, Matas AJ.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (podium).

5. Kidney retransplantation after initial graft loss to vascular thrombosis.  Humar A, Key N, Prieto M, Matas AJ.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (poster).

6 66. Increasing incidence of steroid resistant rejection in kidney transplantation.  Arrazola L, Humar A, Sozen H, Moss A, et al.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (poster).

67. Both immunologic and nonimmunologic factors are risks for long-term graft survival—A multivariate analysis.  Matas AJ, Humar A, Gillingham K.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (poster).

68. Influence of remote and current positive B and T cell cross-match on pancreas transplant.  Hassoun A, Wijkstrom M, Humar A, Moss A, et al.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (poster).

69. Surgical complications in bladder vs. enteric drained simultaneous pancreas kidney (SPK) transplants.  Humar A, Kandaswamy R, Hassoun A, et al.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (poster).

70. Living related bowel transplant and cadaver liver/bowel transplant in the pediatric population.  Humar A, Sharp H, Borne S, Gruessner RW.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (poster).

71. Living unrelated donors in kidney transplants:  better long-term results than Non-HLA identical living related donors?  Humar A, Gillingham K, Matas AJ.  ASTS 25th Annual Meeting.  Chicago, May 1999.  (poster).

72. ABO incompatible, living unrelated, simultaneous kidney-pancreas (SPK) transplant (TX): case report. Kandaswamy R, Wijkstrom M, Eastlund T, Humar A, Sutherland DER.  University of Minnesota.  7th World Congress of the International Pancreas & Islet Transplant Association.  Sydney, Australia, August 1999.  (poster).

73. Gender discrepancy in high-risk pancreas (Pa) transplant (Tx) recipients. Gruessner AC, Drangstveit MB, Humar A, Sutherland DER.  7th World Congress of the International Pancreas & Islet Transplant Association.  Sydney, Australia, August 1999.  (podium).

74. Recipient age and pancreas transplant outcome. Sutherland DER, Gruessner RW, Humar A, Kandaswamy R, Gruessner AC.  7th World Congress of the International Pancreas & Islet Transplant Association.  Sydney, Australia, August 1999.  (podium)

75. Multicenter analysis of daclizumab induction in simultaneous kidney pancreas transplant recipients. Sutherland DER, Humar A, , et al.  7th World Congress of the International Pancreas & Islet Transplant Association.  Sydney, Australia, August 1999.  (podium)

76. Daclizumab (Dmab) therapy in solitary & pancreas (Px)-kidney (Kd) transplantation (Tx). Kandaswamy R, Sutherland DER, Drangstveit MB, Humar A, Chmielewski B, Gruessner AC, University of Minnesota, Minneapolis, MN.  7th World Congress of the International Pancreas & Islet Transplant Association.  Sydney, Australia, August 1999.  (poster)

77. Bladder drainage is safer than enteric drainage in pancreas transplant recipients on peritoneal dialysis.  Humar A, Kandaswamy R, Durand B, Arrazola L, Gruessner RW, Gruessner AC, Sutherland DER.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (poster)

78. Pancreas after kidney (PAK) transplant:  a viable alternative to simultaneous pancreas kidney (SPK) transplant.  Humar A, Kandaswamy R, Parr E, et al.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (poster)

79. Surgical complications in obese pancreas transplant recipients.  Humar A, Kandaswamy R, Drangstveit MB, et al.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (poster)

80. Comparison of single dose intraoperative antithymocyte globulin (ATG) vs Thymoglobulin (TMG) in pancreas (Px) transplants (Tx).  Kandaswamy R, Humar A, Gruessner RW, et al.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (poster)

81. Pancreas (PX) transplantation (TX) alone (PTA) for non-uremic diabetic patients:  a 20-year experience.  Sutherland DER, Gruessner RW, Humar A, Kandaswamy R, et al.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (podium)

82. Improved outcome for pancreas after kidney transplantation (PAK).  Gruessner RW, Sutherland DER, Humar A, Kandaswamy R, Gruessner AC.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (podium)

83. The impact (?) of HLA-ABDR match on chronic rejection (CR).  Matas AJ, Gillingham K, Humar A, Payne WD, Kandaswamy R, et al.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (poster)

84. Increased incidence of late acute rejection (AR) episodes in young pediatric kidney transplant recipients.  Humar A, Arrazola L, Durand B, et al.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (poster)

85. Superficial and deep wound infections developing after kidney transplant (KTx).  Humar A, Kandaswamy R, Papalois V, Arrazola L, Gillingham K, Matas AJ.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (poster)

86. Is there an association between cytomegalovirus (CMV) and renal artery stenosis (RAS) in kidney transplant recipients?  Humar A, Uknis M, Papalois V, Gillingham K, Matas AJ.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (podium)

87. A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation (Pa Tx).  Gruessner RW, Sutherland DER, Parr E, Humar A, Gruessner AC.  Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (podium)

88. Chronic rejection in pancreas transplant recipients:  a multivariate analysis of risk factors.  Humar A, Kandaswamy R, Gruessner RW, Gruessner AC, Sutherland DER.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 13-17, 2000.  (podium)

89. Growth and activity after pediatric liver transplantation:  long term results at a single institution.  Papalois V, Gruessner AC, Sharp H, Humar A, Najarian JS, Payne WD. 1st Congress of the International Pediatric Transplant Association, Venice, August 2000.  (podium)

90. Long term results after pediatric liver transplantation for biliary atresia versus metabolic disorders:  a single institution experience.  Papalois V, Gruessner AC, Sharp H, Humar A, Najarian JS, Payne WD. 1st Congress of the International Pediatric Transplant Association, Venice, August 2000.  (podium)

91. A single center’s long-term experience with 24 pediatric liver transplants for A-1-antitrypsin deficiency.  Papalois V, Gruessner AC, Sharp H, Humar A, Najarian JS, Payne WD. 1st Congress of the International Pediatric Transplant Association, Venice, August 2000.  (podium)

92. Pediatric preemptive renal transplantation in living donor (LD) recipients.  Arrazola L, Humar A, Sozen H, Chavers B, Mauer M, Kashtan C, Nevins T, Gillingham K, Najarian JS, Matas AJ. 1st Congress of the International Pediatric Transplant Association, Venice, August 2000.  (podium)

93. Renal transplantation in children of all ages – age should not determine the timing of transplantation.  Arrazola L, Humar A, Sozen H, Chavers B, Mauer M, Kashtan C, Nevins T, Gillingham K, Najarian JS, Matas AJ. 1st Congress of the International Pediatric Transplant Association, Venice, August 2000.  (podium) 

94. Increased incidence of late acute rejection (AR) in young pediatric kidney transplant recipients.  Arrazola L, Humar A, Sozen H, Chavers B, Mauer M, Kashtan C, Nevins T, Gillingham K, Najarian JS, Matas AJ. 1st Congress of the International Pediatric Transplant Association, Venice, August 2000.  (podium)

95. Kidney transplantation:  acute rejection biomarkers.  Matas AJ, Humar A, W.D. Payne, Kandaswamy R, Dunn DL, Sutherland DER, Najarian JS. 18th International Congress of the Transplantation Society, Rome, August 27 – September 1, 2000.  (poster)

96. Pre-transplant immunosuppression for pancreas (Px) transplants (Txs) alone (PTA) in non-uremic diabetic recipients.  Sutherland DERS, Gruessner RW, Humar A, Kandaswamy R, Najarian JS, Dunn DL, Gruessner AC, 18th International Congress of the Transplantation Society, Rome, August 27 – September 1, 2000.  (podium)

97. Pancreas after kidney transplantation (PAK):  an alternative to simultaneous pancreas and kidney transplantation.  Gruessner RW, Sutherland DER, Dunn DL, Humar A, Kandaswamy R, Gruessner AC. 18th International Congress of the Transplantation Society, Rome, August 27 – September 1, 2000.  (podium)

98. The impact (?) of HLA-ABDR match on chronic rejection (CR).  Gillingham K, Matas AJ, Humar A, Payne WD, Kandaswamy R, Dunn DL, Sutherland DER, Najarian JS, 18th International Congress of the Transplantation Society, Rome, August 27 – September 1, 2000.  (poster)

99. Steroid withdrawal in pancreas transplantation (PA TX):  a prospective, randomized, open-label study.  Gruessner RW, Sutherland DER, Parr E, Humar A, Gruessner AC, 18th International Congress of the Transplantation Society, Rome, August 27 – September 1, 2000.  (poster)

100.  Abdominal wall complications developing after kidney transplant.  Humar A, Gillingham K, Ramcharan T, Matas AJ.  The American Society of Nephrology, Toronto, October 13, 2000.  (poster) 

101. The influence of panel reactive antibodies (PRA) on acute rejection after kidney

 transplant. Humar A, Gillingham K, Ramcharan T, Matas AJ, The American Society 

   of Nephrology, Toronto, October 15, 2000.  (poster)

102. Risk factors for graft loss differ by post transplant interval.  Matas AJ, Gillingham K, Kandaswamy R, Humar A, The American Society of Nephrology 33rd Annual Meeting, Toronto, October 2000.  (podium)

103. Steroid avoidance after living donor transplantation – a pilot study.  Ramcharan T, Schoelkoph L, McHugh L, Humar A, Kandaswamy R, Matas AJ.  The American Society of Nephrology 33rd Annual Meeting, Toronto, October 2000.  (podium) 

104. Incidence of acute rejection (AR) in living donor kidney transplant recipients with azathioprine and optimization of CSA trough levels.  Humar A, Kandaswamy R, Payne WD, Gruessner RW, Sutherland DER.  The American Society of Nephrology 33rd Annual Meeting, Toronto, October 2000.  (podium) 

105. Long-term results with 37 pediatric liver transplants (Txs) for α-1 antitrypsin deficiency (a1AD):  a single center experience.  Ramcharan T, Gruessner AC, Paraskevas S, Humar A, Payne WD, Gruessner RW.  ILTS ELTA Licage, Berlin, 2001.  (podium)

106. Quality of life in elderly recipients of a kidney transplant.  Humar A, Denny R, Mierelles R, Gillingham K, Matas AJ.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

107. Cytokine gene polymorphisms (CGP) in “pancreas transplant alone” (PTA recipients – can they predict outcome?  Kandaswamy R, Humar A, Gruessner AC, Gruessner RW, B. Hering, Matas AJ, Sutherland DER.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001.  (poster).

108. A multivariate analysis of risk factors for slow graft function (SGF) after kidney transplant.  Humar A, Ramcharan T, Paraskevas S, Denny R, Mierelles R, Gillingham K, Matas AJ.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

109. The impact of increasing donor age on long-term kidney graft survival – each year counts.  Humar A, Payne WD, Ramcharan T, Denny R, Gillingham K, Matas AJ.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

110. Pancreas after kidney (PAK) vs. simultaneous pancreas kidney (SPK) transplants:  a comparison of waiting times, cost, and quality of life.  Humar A, Kandaswamy R, Ramcharan T, Paraskevas S, Gruessner RW, Gruessner AC, Sutherland DER.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

111. Non-directed donation:  Who volunteers?  Who is rejected?  Jacobs C, Garvey C, Roman D, Humar A, Matas AJ.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

112. Lymphoceles after kidney transplantation – what’s the best approach for treatment?  Grubbs B, Zapzalka D, Hunter D, Matas AJ, Humar A.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

113. Risk factors for acute rejection (AR) in pancreas transplant recipients:  a multivariate analysis.  Humar A, Kandaswamy R, Ramcharan T, Paraskevas S, Meirelles R, Gruessner RW, Gruessner AC, Sutherland DER.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

114. Sharing of livers for status 1 recipients in region 7 – a good thing.  Humar A, Durand B, Knaak M, Shriver L, Kalis A, Lake J, Payne WD.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

115. Analysis of acute and chronic rejection patterns after pancreas transplant alone (PTA).  Humar A, Kandaswamy R, Ramcharan T, Paraskevas S, Meirelles R, Gruessner RW, Gruessner AC.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (poster).

116. The impact of elderly and pediatric donors on outcome after SPK transplant.  Humar A, Kandaswamy R, Ramcharan T, Paraskevas S, Denny R, Gruessner RW, Gruessner AC, Sutherland DER.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (poster).

117. Outcome after treatment of biopsy proven vs. presumptive acute rejection (AR) in kidney transplant recipients.  Humar A, Kandaswamy R, Denny R, Paraskevas S, Gillingham K, Matas AJ.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001.  (poster).

118. Urologic cancers in kidney transplant recipients.  Gran C, Hulbert J, Roberts K, Jain S, Matas AJ, Humar A.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (poster).

119. Kidney cancers in renal transplant recipients.  Gran C, Hulbert J, Roberts K, Jain S, Matas AJ, Humar A.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (poster).

120. Outcome of other organs recovered during in situ split liver procurements.  Ramcharan T, Rogers M, Kandaswamy R, Sielaff T, Gruessner RW, Lake J, Payne WD, Humar A.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (poster).

121. Split-liver transplant for 2 adult recipients:  an initial experience.  Humar A, Kandaswamy R, Sielaff T, Gruessner RW, Knaak M, Lake J, Payne WD.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (poster).

122. Who becomes a non-directed kidney donor?  Jacobs C, Roman D, Garvey C, Humar A, Matas AJ.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (poster).

123. Improvements from steroid withdrawal after pancreas transplantation:  1-year results of a prospective randomized open-label study.  Gruessner RW, Sutherland DER, Parr E, Humar A, Kandaswamy R, Gruessner AC.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

124. Living kidney donation:  long-term (20-37 yrs.) consequences.  Ramcharan T, McHugh L, Kandaswamy R, Gruessner RW, Payne WD, Sutherland DER, Humar A, Dunn DL, Najarian JS, Matas AJ.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (podium).

125. Long-term cyclosporine immunosuppression:  Is there nephrotoxicity in kidney transplant recipients?  Paraskevas S, Denny R, Ramcharan T, Gillingham K, Kandaswamy R, Humar A, Matas AJ.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001. (poster).

126. Steroid avoidance (minimization) after kidney transplantation.  Matas AJ, Ramcharan T, Paraskevas S, Kandaswamy R, Humar A, Gillingham K.  Annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  Chicago, Illinois, May 11-16, 2001.  (podium).

127. Risk factors for acute rejection (AR) in pancreas transplant recipients:  a multivariate analysis.  Humar A, Kandaswamy R, Ramcharan T, Paraskevas S, Meirelles R, Gruessner RW, Gruessner AC, Sutherland DER.  8th World Congress International Pancreas and Islet Transplantation Association.  Innsbruck, Austria, June 12-15, 2001.  (podium)

128. The impact of elderly and pediatric donors on outcome after SPK transplant.  Humar A, Kandaswamy R, Ramcharan T, Paraskevas S, Denny R, Gruessner RW, Gruessner AC, Sutherland DER.  8th World Congress International Pancreas and Islet Transplantation Association.  Innsbruck, Austria, June 12-15, 2001.  (podium)

129. Analysis of cute and chronic rejection patterns after pancreas transplant alone (PTA).  Humar A, Kandaswamy R, Ramcharan T, Paraskevas S, Meirelles R, Grussner RW, Gruessner AC.  8th World Congress International Pancreas and